1.0.0 AbstractMalaria is a major problem in Africa, in 2006 causing around 200 million episodes of disease. Worldwide, over 1 million people die of this disease each year. Plasmodium falciparum is the dominating parasite in Western Africa and is the reason of most deaths due to malaria. There has been a problem with resistance against chlorochine, which is a cheap and easy available antimalarial drug. WHO now recommends artemisinin-based combination therapy (ACT) which is more efficient and less vulnerable for the development of resistance. Most of the malariaendemic countries worldwide have now adopted this regime of treatment. There are four types of ACT recommended by the WHO: arthemeter-lumefantrine (Coartem), artesunate+amodiaquine (ASAQ), artesunate+mefloquine and artesunate+sulfadoxine-pyrimethamine. Two of these drug regimes are available as combination tablets (Coartem and ASAQ), which increases compliance. In February 2008, The Gambia changed their treatment regime for uncomplicated malaria to Coartem, and this lead to a decreasing number of deaths due to malaria. The treatment for severe malaria is recommended to be parenteral quinine, which is widely used, or parenteral artesunate. Besides treatment, prevention of malaria is important. Insecticide treated mosquito nets (ITN) are distributed all over Sub-Saharian Africa, and are primarily given pregnant women and children under five years. Pregnant woman are also given intermittent preventive treatment (IPT); which is two doses of sulfadoxine-pyrimethamine, one dose given in the second, and one given in the third trimester. Besides this, indoor residual spraying (IRS) contributes to prevention of malaria by reducing the life span and density of mosquitoes.